1-20 of 91
Ludek Pour
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Meletios Dimopoulos, Thierry Facon, Meral Beksac, Ludek Pour, Roman Hajek, Zhuogang Liu, Jiri Minarik, Philippe Moreau, Joanna Romejko-Jarosinska, Ivan Špička, Vladimir I. Vorobyev, Britta Besemer, Tadao Ishida, Wojciech Janowski, Sevgi Kalayoglu Besisik, Gurdeep Parmar, Pawel Robak, Elena Zamagni, Hartmut Goldschmidt, Thomas Martin, Salomon Manier, Mohamad Mohty, Robert Z. Orlowski, Erin Comerford, Claire Tian, Jérôme Msihid, Feng Lin, Stephanie Rhoten, Xavier. P Leleu
Journal: Blood
Blood (2024) 144 (Supplement 1): 3352.
https://doi.org/10.1182/blood-2024-207087
Published: 2024
Journal Articles

Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets - Analysis of the Czech Myeloma Group

Jiri Minarik, Luděk Pour, Tomas Jelinek, Ivan Spicka, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Tomas Pika, Stork Martin, Jan Straub, Vojtech Latal, Dominik Fric, Vladimir Maisnar, Roman Hajek
Journal: Blood
Blood (2024) 144 (Supplement 1): 2378.
https://doi.org/10.1182/blood-2024-200014
Published: 2024
Journal Articles

A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma

Tereza Popkova, Jakub Radocha, Martin Stork, Jiří Minařík, Jan Straub, Alexandra Jungova, Petr Pavlicek, Tomas Jelinek, Vladimir Maisnar, Ludek Pour, Tomas Pika, František Sedlák, Jan Soukup, Hana Plonkova, Ludmila Muronova, Viera Sandecka, Petra Krhovska, David Zihala, Roman Hajek
Journal: Blood
Blood (2024) 144 (Supplement 1): 1999.
https://doi.org/10.1182/blood-2024-211224
Published: 2024
Journal Articles

First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma

Fredrik Schjesvold, Tomas Jelinek, Kamila Polgarova, Ludek Pour, Sung-Soo Yoon, Won Seog Kim, Alexander Fosså, Jesús F. San-Miguel, Miguel Canales, Paula Rodríguez-Otero, Albert Oriol, Javier de la Rubia, Joaquín Martínez-Lopez, Sonia González De Villambrosia, Prashant Kapoor, Ola Landgren, James Edward Hoffman, Noopur Raje, Hongfang Wang, Kunal Jhunjhunwala, Liang Zhao, Zhini Wang, Mony Morisse, Helgi Van de Velde, Nitya Nathwani
Journal: Blood
Blood (2024) 144 (Supplement 1): 1992.
https://doi.org/10.1182/blood-2024-204614
Published: 2024
Journal Articles

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients - Czech Multi-Center Real World Evidence Analysis

Martin Stork, Jakub Radocha, Tomas Jelinek, Ivan Spicka, Tomas Pika, Alexandra Jungova, Jan Straub, Jiri Minarik, Ivanna Boichuk, Dominik Fric, Denisa Novakova, Tereza Popkova, Lenka Polcerova, Vladimir Maisnar, Ludek Pour, Roman Hajek
Journal: Blood
Blood (2024) 144 (Supplement 1): 5156.
https://doi.org/10.1182/blood-2024-202002
Published: 2024
Journal Articles

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Meral Beksac, Esther Gonzalez Garcia, Sosana Delimpasi, Pawel Robak, Kamaraj Karunanithi, Felipe De Arriba, Jakub Radocha, Kihyun Kim, Sergey Voloshin, Vera Zherebtsova, Iurii Osipov, Maria-Victoria Mateos, Syed F. Zafar, Luděk Pour, Ivan Spicka, Kazuhito Suzuki, Xin Du, Jodie Wilkes, Brijesh Maroj, Kristin Morris, Jie Ma, Margaret Polinkovsky, Zhaohui Wang, Xiaoou L Zhou, Giulia Fulci, Neal Sule, Brandon Kremer, Joanna Opalinska, Suzanne Trudel, Meletios A. Dimopoulos
Journal: Blood
Blood (2024) 144 (Supplement 1): 4731.
https://doi.org/10.1182/blood-2024-199282
Published: 2024
Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Sonja Zweegman, Thierry Facon, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Luděk Pour, Josep Marti Tutusaus, Supratik Basu, Yael C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Maciej Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Weiping Liu, Jianping Wang, Katherine Chastain, Jessica Vermeulen, Maria Krevvata, Lorena Lopez-Masi, Jodi Carey, Melissa Rowe, Robin Carson, Saad Z. Usmani
Journal: Blood
Blood (2024) 144 (Supplement 1): 362.
https://doi.org/10.1182/blood-2024-200871
Published: 2024
Journal Articles

Comparison of Lenalidomide Based Triplets (IRD, KRD and DRD) in Relapsed and Refractory Multiple Myeloma in Routine Practice

Jiri Minarik, Ludek Pour, Tomas Jelinek, Ivan Spicka, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Tomas Pika, Martin Stork, Jan Straub, Vladimir Maisnar, Roman Hajek
Journal: Blood
Blood (2023) 142 (Supplement 1): 4733.
https://doi.org/10.1182/blood-2023-179299
Published: 2023
Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Barry Paul, Jirí Minarík, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Mitul Gandhi, Jens Hillengass, Moshe Levy, Michaela Liedtke, Sudhir Manda, Irwindeep Sandhu, Douglas Sborov, Ivan Spicka, Saad Z Usmani, Lin Gu, Michelle Robeson, Michael Murphy, Camille Renard, Christine Chen, Luděk Pour
Journal: Blood
Blood (2023) 142 (Supplement 1): 3383.
https://doi.org/10.1182/blood-2023-186997
Published: 2023
Journal Articles

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Francesca Gay, Wilfried Roeloffzen, Meletios A. Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol Rocafiguera, Eirini Katodritou, Ka Lung Wu, Paula Rodriguez Otero, Roman Hajek, Elisabetta Antonioli, Mark van Duin, Mattia D'Agostino, Joaquin Martinez-Lopez, Elena M. van Leeuwen-Segarceanu, Paola Tacchetti, Niels W.C.J. van de Donk, Katja Weisel, Luděk Pour, Jakub Radocha, Angelo Belotti, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Annemiek Broijl
Journal: Blood
Blood (2023) 142 (Supplement 1): 4.
https://doi.org/10.1182/blood-2023-177546
Published: 2023
Journal Articles

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Fredrik Schjesvold, Meletios A. Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Maciej Legiec, Ludek Pour, Ivan Spicka, Tamas Masszi, Vadim Anatolievich Doronin, Jiri Minarik, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimir Maisnar, Gabor Mikala, Stefan Norin, Marcus Thuresson, Anna Bergan, Jakob Obermüller, Roman Hajek, Maria-Victoria Mateos, Paul G. Richardson, Pieter Sonneveld
Journal: Blood
Blood (2023) 142 (Supplement 1): 2018.
https://doi.org/10.1182/blood-2023-177945
Published: 2023
Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis

Thierry Facon, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Andreea Rawlings, Christina Tekle, Sandrine Schwab, Marie-Laure Risse, Thomas Martin
Journal: Blood
Blood (2022) 140 (Supplement 1): 1820–1822.
https://doi.org/10.1182/blood-2022-159105
Published: 2022
Journal Articles

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Maria-Victoria Mateos, Jesús San-Miguel, Michele Cavo, Joan Bladé Creixenti, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ludek Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Meletios A. Dimopoulos
Journal: Blood
Blood (2022) 140 (Supplement 1): 10157–10159.
https://doi.org/10.1182/blood-2022-163347
Published: 2022
Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Niels W.C.J. Van De Donk, Monique C. Minnema, Bronno van der Holt, Fredrik Schjesvold, Ka Lung Wu, Andrea Capra, Annemiek Broijl, Wilfried W.H. Roeloffzen, Alain Gadisseur, Giuseppe Pietrantuono, Ludek Pour, Vincent H.J. van der Velden, Thomas Lund, Massimo Offidani, Mariella Grasso, Luisa Giaccone, Michele Cavo, Trine Silkjaer, Jo Caers, Sonja Zweegman, Roman Hájek, Reuben Benjamin, Annette Juul Vangsted, Mario Boccadoro, Francesca Gay, Pieter Sonneveld, Pellegrino Musto
Journal: Blood
Blood (2022) 140 (Supplement 1): 4420–4422.
https://doi.org/10.1182/blood-2022-165942
Published: 2022
Journal Articles

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Pellegrino Musto, Monique C. Minnema, Wilfried W.H. Roeloffzen, Andrea Capra, Bronno van der Holt, Annette Juul Vangsted, Annemiek Broijl, Fredrik Schjesvold, Thomas Lund, Trine Silkjaer, Reuben Benjamin, Mariella Grasso, Ka Lung Wu, Jo Caers, Michele Cavo, Roman Hájek, Benedetto Bruno, Alain Gadisseur, Giuseppe Pietrantuono, Massimo Offidani, Luděk Pour, Pieter Sonneveld, Mario Boccadoro, Niels W.C.J. van de Donk
Journal: Blood
Blood (2022) 140 (Supplement 1): 4409–4411.
https://doi.org/10.1182/blood-2022-156390
Published: 2022
Journal Articles

PORT (OP-109): Phase 2, Randomized, Pharmacokinetic (PK), Cross-over Study of Peripheral Vs Central Intravenous Administration of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Jiri Minarik, Ilina Micheva, Ganna Usenko, Gabor Mikala, Kameliya Simeonova, Marcus Thuresson, Markus Jerling, Hanjing Xie, Ludek Pour
Journal: Blood
Blood (2021) 138 (Supplement 1): 4772.
https://doi.org/10.1182/blood-2021-150639
Published: 2021
Journal Articles

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Tereza Popkova, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Tomas Jelinek, Petr Pavlicek, Marta Krejci, Jan Straub, Vladimir Maisnar, Tereza Dekojova, Tomas Pika, Jan Soukup, Lenka Capkova, Roman Hájek
Journal: Blood
Blood (2021) 138 (Supplement 1): 4894.
https://doi.org/10.1182/blood-2021-153978
Published: 2021
Journal Articles

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis

Tadeusz Robak, Sosana Delimpasi, Ludek Pour, Tamas Masszi, Ivan Spicka, Wojciech Legiec, Pieter Sonneveld, Marcus Thuresson, Kajsa Larsson, Johan Harmenberg, Fredrik H. Schjesvold
Journal: Blood
Blood (2021) 138 (Supplement 1): 4777.
https://doi.org/10.1182/blood-2021-146550
Published: 2021
Journal Articles

Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia

Tomas Jelinek, Renata Bezděková, David Zihala, Tereza Sevcikova, Lenka Capkova, Petra Polackova, Martin Stork, Zdenka Knechtova, Ondrej Venglar, Artur Jurczyszyn, Jorge J. Castillo, Miroslav Penka, Jakub Radocha, Sabina Sevcikova, Ludek Pour, Lucie Rihova, Roman Hajek
Journal: Blood
Blood (2021) 138 (Supplement 1): 546.
https://doi.org/10.1182/blood-2021-151592
Published: 2021
Journal Articles

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Jiri Minarik, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika, Ludek Pour, Petr Pavlicek, Lubica Harvanova, Lenka Capkova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Martin Mistrik, Jaroslav Bacovsky, Vladimir Maisnar, Roman Hajek
Journal: Blood
Blood (2021) 138 (Supplement 1): 2716.
https://doi.org/10.1182/blood-2021-148836
Published: 2021